Summary

Hanna Kim is a pediatric rheumatologist who studied interferon-mediated autoinflammatory disease, novel biomarkers, pharmacokinetics and pharmacodynamics in a compassionate use study during fellowship at NIAMS/NIH.  Currently, as a Lawrence Shulman Scholar, she is focused on studying pathogenesis including the role of interferon and identifying activity-related biomarkers in juvenile myositis, particularly juvenile dermatomyositis.

Research Statement

Hanna Kim’s current research interest is pathogenesis and biomarker discovery utilizing transcriptomic and proteomic analysis in juvenile dermatomyositis (JDM), an autoimmune inflammatory myopathy.  Particular focus is placed on how this disease compares with Mendelian autoinflammatory diseases, identification of disease-activity related biomarkers, and myositis autoantibody subgroups. The overall goal of this translational research in JDM to identify more targeted therapies with decreased adverse effects and better monitor disease activity and treatment response.

Education

California Institute of Technology (Caltech)
B.S.

University of California at Irvine (UCI)
M.D.

Experience

Residency in Pediatrics
George Washington University / Children’s National Medical Center

Pediatric Rheumatology Fellowship
Nemours/Alfred I. DuPont Hospital for Children (Wilmington, DE), Children’s National Health System (DC), and NIH-NIAMS.

Last Reviewed: 03/03/2017